Supplementary Figures 1 - 7 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Autor: Patrick Hwu, Audrey Gonzalez, Seth Wardell, Renjith Ramachandran, Christopher Toth, Orenthial J. Fulbright, Rahmatu Mansaray, Michael A. Davies, Janice N. Cormier, Richard Royal, Anthony Lucci, Jeffrey E. Gershenwald, Jeffrey E. Lee, Merrick I. Ross, Sapna Patel, Wen-Jen Hwu, Agop Bedikian, Jade Homsi, Kevin Kim, Nicholas Papadopoulos, Victor Prieto, Elizabeth Shpall, John D. McMannis, Valen E. Johnson, Michelle Glass, Gladys Alvarado, Sandy Mahoney, Gregory Lizee, Richard Wu, Jessica Chacon, Priscilla Miller, Patricia S. Fox, Minying Zhang, Chantale Bernatchez, Laszlo G. Radvanyi
Rok vydání: 2023
DOI: 10.1158/1078-0432.22452188.v1
Popis: PDF file - 1856K, Fig. S1. Schema of TIL adoptive cell therapy clinical trial; Fig. S2. Recovery of total white blood cell counts (WBC), absolute lymphocyte counts (ALC), and absolute neutrophil counts (ANC) during adoptive transfer TIL therapy in 31 treated patients; Fig. S3. Durable partial response of an intrathoracic melanoma mass near the aorta and heart in one patient at 6 weeks and 18 months after TIL infusion; Figure S4. Kaplan-Meier curves of overall survival and progression-free survival for all 31 treated patients; Figure S5. Kaplan-Meier curves of landmark-based overall survival and progression-free survival for irRC responding and non-responding TIL-treated patients; Fig. S6. Change in tumor burden over the first 20-22 months following TIL transfer therapy in responders and non-responders; Fig. S7. Box and whisker plot showing that telomere length of infused TIL was not significantly different between responders and non-responders
Databáze: OpenAIRE